Citations

Clear

9383 citation(s) found for "Thomas, PS".

Pharmacy informatics: Aligning for success
Siska, Mark H., Meyer, Gerald E.

Mayo Clinic

American Journal of Health-System Pharmacy | July 24, 2008 | Volume: 65 | Issue: 15 | Pages: 1410-1411

10.2146/ajhp070527 | PMID 18653810 Get It

P2‐461: Selective modulation of gamma‐secretase cleavage of the amyloid precursor family of proteins
Kukar, Thomas , Osenkowski, Pamela, Engel, Paul C., Wolfe, Michael S. , Golde, Todd E. , Walsh, Dominic M. , Frigerio, Carlo Sala

Mayo Clinic

Alzheimer's & Dementia | July 24, 2008 | Volume: 4 | Issue: 4S_Part_15 | Pages: No page available

10.1016/j.jalz.2008.05.1540 Get It

P4‐387: Adding delayed recall to the Alzheimer's disease assessment scale‐cognitive subscale (ADAS‐cog): Sensitivity in a clinical trial for Alzheimer's disease and mild cognitive impairment
Raman, Rema , Thomas, Ronald G. , Petersen, Ronald , Schneider, Lon S. , Aisen, Paul, Sano, Mary , Emond, Jennifer A.

Mayo Clinic

Alzheimer's & Dementia | July 24, 2008 | Volume: 4 | Issue: 4S_Part_24 | Pages: No page available

10.1016/j.jalz.2008.05.2457 Get It

IC‐P3‐212: Mapping the binding site of gamma‐secretase modulators by small (and not so small) organic molecules
Baumann, Stefanie , Hoettecke, Nicole, Narlawar, Rajeshwar , Kukar, Thomas , Golde, Todd E. , Baumann, Karlheinz, Schmidt, Boris

Mayo Clinic

Alzheimer's & Dementia | July 24, 2008 | Volume: 4 | Issue: 4S_Part_3 | Pages: No page available

10.1016/j.jalz.2008.05.157 Get It

P1‐228: Comparison of amyloid plaque contrast generated by T2‐, T2*, and susceptibility‐weighted magnetic resonance imaging methods in transgenic mice
Chamberlain, Ryan , Reyes, Denise , Curran, Geoffrey L., Wengenack, Thomas M., Poduslo, Joseph F., Marjańska, Małgorzata , Garwood, Michael , Jack, Clifford R.

Mayo Clinic

Alzheimer's & Dementia | July 24, 2008 | Volume: 4 | Issue: 4S_Part_8 | Pages: No page available

10.1016/j.jalz.2008.05.817 Get It

P1‐052: Somatic brain transgenic TDP‐43 mice
Verbeeck, Christophe , Cannon-Crews, Ashley, Jansen‐West, Karen , Ceballos‐Diaz, Carolina, Golde, Todd E. , Kukar, Thomas , McGowan, Eileen

Mayo Clinic

Alzheimer's & Dementia | July 24, 2008 | Volume: 4 | Issue: 4S_Part_7 | Pages: No page available

10.1016/j.jalz.2008.05.638 Get It

IC‐P1‐008: Comparison of amyloid plaque contrast generated by T2‐, T2*, and susceptibility‐weighted magnetic resonance imaging methods in transgenic mice
Chamberlain, Ryan , Reyes, Denise A., Curran, Geoffrey L., Wengenack, Thomas M., Poduslo, Joseph F., Marjańska, Małgorzata , Garwood, Michael , Jack, Clifford R.

Mayo Clinic

Alzheimer's & Dementia | July 24, 2008 | Volume: 4 | Issue: 4S_Part_1 | Pages: No page available

10.1016/j.jalz.2008.05.021 Get It

A γ-secretase inhibitor and quinacrine reduce prions and prevent dendritic degeneration in murine brains
Spilman, Patricia , Lessard, Pierre, Sattavat, Mamta, Bush, Clarissa, Tousseyn, Thomas , Huang, Eric J. , Giles, Kurt, Golde, Todd E. , Das, Pritam , Fauq, Abdul H. , Prusiner, Stanley B. , DeArmond, Stephen J.

Mayo Clinic

Proceedings of the National Academy of Sciences | July 22, 2008 | Volume: 105 | Issue: 30 | Pages: 10595-10600

10.1073/pnas.0803671105 | PMID 18647832 Get It

In prion-infected mice, both the Notch-1 intracellular domain transcription factor (NICD) and the disease-causing prion protein (PrP Sc ) increase in the brain preceding dendritic atrophy and loss. Because the drug LY411575 inhibits the γ-secretase-catalyzed cleavage of Notch-1 that produces NICD, we asked whether this γ-secretase inhibitor (GSI) might prevent dendritic degeneration in mice with scrapie. At 50 d postinoculation with Rocky Mountain Laboratory (RML) prions, mice were given GSI orally for 43–60 d. Because we did not expect GSI to produce a reduction of PrP Sc levels in brain, we added quinacrine (Qa) to the treatment regimen. Qa inhibits PrP Sc formation in cultured cells. The combination of GSI and Qa reduced PrP Sc by ≈95% in the neocortex and hippocampus but only ≈50% in the thalamus at the site of prion inoculation. The GSI plus Qa combination prevented dendritic atrophy and loss, but GSI alone did not. Even though GSI reduced NICD levels to a greater extent than GSI plus Qa, it was unable to prevent dendritic degeneration. Whether a balance between NICD and dendrite growth-stimulating factors was achieved with GSI plus Qa but not GSI alone remains to be determined. Although the combination of GSI and Qa diminished PrP Sc in the brains of RML-infected mice, GSI toxicity prevented us from being able to assess the effect the GSI plus Qa combination on incubation times. Whether less toxic GSIs can be used in place of LY411575 to prolong survival remains to be determined.
Host immune gene polymorphisms in combination with clinical and demographic factors predict late survival in diffuse large B-cell lymphoma patients in the pre-rituximab era
Wang, Sophia , Maurer, Matthew J. , Morton, Lindsay M. , Lynch, Charles F. , Ansell, Stephen M. , Hartge, Patricia, Severson, Richard K., Rothman, Nathaniel , Geyer, Susan M. , Cerhan, James R. , Habermann, Thomas M. , Davis, Scott , Cozen, Wendy , Chanock, Stephen Jacob , Maurer, Matthew , Cerhan, James R , Morton, Lindsay M , Wang, Sophia S

Mayo Clinic

Blood | July 17, 2008 | Volume: 112 | Issue: 7 | Pages: 2694-2702

10.1182/blood-2007-09-111658 | PMID 18633131 Get It

AbstractTo evaluate the hypothesis that host germ line variation in immune genes is associated with overall survival in diffuse large B-cell lymphoma (DLBCL), we genotyped 73 single nucleotide polymorphisms (SNPs) from 44 candidate genes in 365 DLBCL patients diagnosed from 1998 to 2000. We estimated hazard ratios (HRs) and 95% confidence intervals (CIs) for the association of SNPs with survival after adjusting for clinical factors. During follow-up, 96 (26%) patients died, and the median follow-up was 57 months for surviving patients. The observed survival of this cohort was consistent with population-based estimates conditioned on surviving 12 months. An IL10 haplotype (global P = .03) and SNPs in IL8RB (rs1126580; HRAG/GG = 2.11; CI, 1.28-3.50), IL1A (rs1800587; HRCT/TT = 1.90; CI, 1.26-2.87), TNF (rs1800629; HRAG/GG = 1.44; CI, 0.95-2.18), and IL4R (rs2107356; HRCC/CT = 1.97; CI, 1.01-3.83) were the strongest predictors of overall survival. A risk score that combined the latter 4 SNPs with clinical factors was strongly associated with survival in a Cox model (P = 6.0 × 10−11). Kaplan-Meier 5-year survival estimates for low, intermediate-low, intermediate-high, and high-risk patients were 94%, 79%, 60%, and 48%, respectively. These data support a role for germ line variation in immune genes, particularly genes associated with a proinflammatory state, as predictors of late survival in DLBCL.